文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症心脑血管急症

加拿大阿尔伯塔省与安大略省COVID-19大流行前后非COVID-19疾病住院患者结局比较

Outcomes Among Patients Hospitalized With Non-COVID-19 Conditions Before and During the COVID-19 Pandemic in Alberta and Ontario, Canada.
PubMed 文献 · JAMA Netw Open · 2023-07-03
一句话结论大流行期间,非COVID-19住院患者中仅心衰及COPD或哮喘患者30天死亡风险升高,其余病种结局与疫情前相似,即使COVID-19病例激增。

这项在加拿大阿尔伯塔省和安大略省235家急性护理医院开展的回顾性队列研究,比较了2018年4月1日至2019年9月30日(大流行前)与2020年4月1日至2021年9月30日(大流行期间)因心衰、COPD或哮喘、尿路感染或尿源性脓毒症、急性冠脉综合征或卒中住院的成人患者。主要结局为入院后30天全因死亡,采用分层多变量回归模型分析。结果显示,大流行期间合并SARS-CoV-2感染的患者住院时间更长(平均8.6天,中位数延长6天,范围1-22天)且死亡率更高(30天绝对增加平均4.7%);未合并感染的患者中,仅心衰(AOR 1.16;95%CI 1.09-1.24)和COPD或哮喘(AOR 1.41;95%CI 1.30-1.53)的30天死亡风险升高。随着COVID-19病例激增,非COVID-19患者结局稳定,但当激增指数超过第99百分位时,30天死亡AOR为1.80(95%CI 1.24-2.61)。

要点

  • 大流行期间未合并SARS-CoV-2感染的非COVID-19住院患者中,仅心衰(AOR 1.16;95%CI 1.09-1.24)和COPD或哮喘(AOR 1.41;95%CI 1.30-1.53)的30天死亡风险较疫情前升高。
  • 合并SARS-CoV-2感染的选择性疾病患者住院时间平均8.6天(中位数延长6天,范围1-22天),30天死亡率绝对增加平均4.7%。
  • 当医院COVID-19激增指数超过第99百分位时,患者30天死亡AOR为1.80(95%CI 1.24-2.61),高于激增指数低于第75百分位时。
  • 除心衰和COPD或哮喘外,大多数非COVID-19且SARS-CoV-2检测阴性的住院患者在大流行期间的风险调整结局与疫情前相似,即使COVID-19病例激增。

适用人群与场景

  • 纳入2018年4月1日至2019年9月30日(大流行前)及2020年4月1日至2021年9月30日(大流行期间)在加拿大阿尔伯塔省和安大略省235家急性护理医院住院的成人患者,主要诊断为此前选定的5种疾病:心衰、COPD或哮喘、尿路感染或尿源性脓毒症、急性冠脉综合征或卒中。
  • 大流行期间队列中114 414例(99.3%)SARS-CoV-2检测阴性。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量:大流行前132 240例(平均[SD]年龄71.8[14.8]岁;女性61 493例[46.5%],男性70 747例[53.5%]),大流行期间115 225例(平均[SD]年龄71.9[14.7]岁;女性52 058例[45.2%],男性63 167例[54.8%]);设置:加拿大阿尔伯塔省和安大略省235家急性护理医院。
  • 暴露:2020年4月至2021年9月各医院每月激增指数(相对基线床位容量的COVID-19病例负荷)。
  • 主要结局:5种选定疾病或COVID-19入院后30天全因死亡,采用分层多变量回归模型分析;次要结局为住院时间。
  • 大流行期间合并SARS-CoV-2感染的选择性疾病患者住院时间平均[SD]8.6[7.1]天,中位数延长6天(范围1-22天),30天死亡率绝对增加平均[SD]4.7%[3.1%],均高于未合并感染者。
  • 未合并SARS-CoV-2感染的选择性疾病患者,大流行期间住院时间与疫情前相似;仅心衰(AOR 1.16;95%CI 1.09-1.24)和COPD或哮喘(AOR 1.41;95%CI 1.30-1.53)的30天死亡风险较疫情前升高。
  • 随着医院COVID-19病例激增,选择性疾病患者的住院时间和风险调整死亡率保持稳定,但COVID-19患者更高;激增指数超过第99百分位时,30天死亡AOR为1.80(95%CI 1.24-2.61),而激增指数低于第75百分位时作为参照。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,大多数非COVID-19且SARS-CoV-2检测阴性的住院患者(其心衰和COPD或哮喘除外)在大流行期间的风险调整结局与疫情前相似,即使COVID-19病例激增,提示在区域或医院特定 occupancy 压力下具有韧性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The association of inpatient COVID-19 caseloads with outcomes in patients hospitalized with non-COVID-19 conditions is unclear.

OBJECTIVE: To determine whether 30-day mortality and length of stay (LOS) for patients hospitalized with non-COVID-19 medical conditions differed (1) before and during the pandemic and (2) across COVID-19 caseloads.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study compared patient hospitalizations between April 1, 2018, and September 30, 2019 (prepandemic), vs between April 1, 2020, and September 30, 2021 (during the pandemic), in 235 acute care hospitals in Alberta and Ontario, Canada. All adults hospitalized for heart failure (HF), chronic obstructive pulmonary disease (COPD) or asthma, urinary tract infection or urosepsis, acute coronary syndrome, or stroke were included.

EXPOSURE: The monthly surge index for each hospital from April 2020 through September 2021 was used as a measure of COVID-19 caseload relative to baseline bed capacity.

MAIN OUTCOMES AND MEASURES: The primary study outcome was 30-day all-cause mortality after hospital admission for the 5 selected conditions or COVID-19 as measured by hierarchical multivariable regression models. Length of stay was the secondary outcome.

RESULTS: Between April 2018 and September 2019, 132 240 patients (mean [SD] age, 71.8 [14.8] years; 61 493 female [46.5%] and 70 747 male [53.5%]) were hospitalized for the selected medical conditions as their most responsible diagnosis compared with 115 225 (mean [SD] age, 71.9 [14.7] years, 52 058 female [45.2%] and 63 167 male [54.8%]) between April 2020 and September 2021 (114 414 [99.3%] of whom had negative SARS-CoV-2 test results). Patients admitted during the pandemic with any of the selected conditions and concomitant SARS-CoV-2 infection exhibited a much longer LOS (mean [SD], 8.6 [7.1] days or a median of 6 days longer [range, 1-22 days]) and greater mortality (varying across diagnoses, but with a mean [SD] absolute increase at 30 days of 4.7% [3.1%]) than those without coinfection. Patients hospitalized with any of the selected conditions without concomitant SARS-CoV-2 infection had similar LOSs during the pandemic as before the pandemic, and only patients with HF (adjusted odds ratio [AOR], 1.16; 95% CI, 1.09-1.24) and COPD or asthma (AOR, 1.41; 95% CI, 1.30-1.53) had a higher risk-adjusted 30-day mortality during the pandemic. As hospitals experienced COVID-19 surges, LOS and risk-adjusted mortality remained stable for patients with the selected conditions but were higher in patients with COVID-19. Once capacity reached above the 99th percentile, patients' 30-day mortality AOR was 1.80 (95% CI, 1.24-2.61) vs when the surge index was below the 75th percentile.

CONCLUSIONS AND RELEVANCE: This cohort study found that during surges in COVID-19 caseloads, mortality rates were significantly higher only for hospitalized patients with COVID-19. However, most patients hospitalized with non-COVID-19 conditions and negative SARS-CoV-2 test results (except those with HF or with COPD or asthma) exhibited similar risk-adjusted outcomes during the pandemic as before the pandemic, even during COVID-19 caseload surges, suggesting resiliency in the event of regional or hospital-specific occupancy strains.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. McAlister FA, Chu A, Qiu F, et al. Outcomes Among Patients Hospitalized With Non-COVID-19 Conditions Before and During the COVID-19 Pandemic in Alberta and Ontario, Canada. JAMA Netw Open. 2023. PMID: 37436751. doi:10.1001/jamanetworkopen.2023.23035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。